De Virgilio Armando, Costantino Andrea, Festa Bianca Maria, Mercante Giuseppe, Franceschini Davide, Franzese Ciro, Scorsetti Marta, Marrari Andrea, Cavina Raffaele, Marano Salvatore, Castoro Carlo, Spriano Giuseppe
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
J Cancer Res Clin Oncol. 2023 Mar;149(3):1369-1371. doi: 10.1007/s00432-022-04441-z. Epub 2022 Oct 29.
In a previous study, we performed a meta-analysis of the oncological outcomes of patients suffering from cervical esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Further analysis was performed, and a random effect modeling showed a pooled local-regional failure rate of 41.4% (95% CI 32.2-50.8), and a pooled distant failure rate of 21.6% (95% CI 17.0-26.5). The included studies used a median radiotherapy (RT) dose of 61.2 Gy (95% CI 60.0-62.0, range 56.0-66.0), but we measured a non-significant impact of the RT dose on the pooled overall survival (OS), suggesting that an increased RT dose might not be related to an improved OS (p = 0.23). Further research should be conducted to define predictors and prognostic categories that may select the best treatment option for each patient.
在之前的一项研究中,我们对接受根治性放化疗的颈段食管鳞状细胞癌患者的肿瘤学结局进行了荟萃分析。我们进行了进一步分析,随机效应模型显示局部区域复发率合并为41.4%(95%可信区间32.2 - 50.8),远处复发率合并为21.6%(95%可信区间17.0 - 26.5)。纳入研究中放疗(RT)剂量中位数为61.2 Gy(95%可信区间60.0 - 62.0,范围56.0 - 66.0),但我们发现RT剂量对合并总生存期(OS)的影响无统计学意义,这表明增加RT剂量可能与改善OS无关(p = 0.23)。应开展进一步研究以确定可能为每位患者选择最佳治疗方案的预测因素和预后类别。